Parenteral Nutrition–Associated Hyperglycemia in Non–Critically Ill Inpatients Increases the Risk of In-Hospital Mortality (Multicenter Study)

Gabriel Oliveira, PhD1,2
María Jose Tapia, MD1
Julia Ocon, PhD3
Carmen Cabrejas-Gomez, MD3
María D. Ballesteros-Pomar, PhD4
Alfonso Vidal-Casariego, MD5
Carmen Arraiza-Irigoyen, MD5
Josefina Olivares, MD6
María del Carmen Conde-García, MD7
Alvaro García-Manzanares, MD7
Francisco Botella-Romero, PhD8
Rosa P. Quiñez-Torosso, MD9
Lucio Cabreroz, PhD9
Pilar Matia, MD9
Luisa Chicharro, PhD10
Rosa Burgos, PhD10
Pedro Pujante, MD11
Mercedes Ferrer, PhD11
Ana Zugasti, PhD12
Javier Prieto, MD13
María Dieguez, MD13
María Jose Carrera, MD14
Anna Vil-Bundo, MD14
Juan Ramon Urieges, MD15
Carmen Aragon-Valera, MD16
Adela Rovira, PhD16
Irene Breton, MD17
Pilar García-Peris, PhD17
Araqueli Munoz-Garach, MD18
Efren Marquez, PhD18
Dolores del Olmo, PhD19
José Luis Pereira, MD19
Maria C. Tous, MD19

Study Group of Hyperglycemia in Parenteral Nutrition: Nutrition Area of the Spanish Society of Endocrinology and Nutrition (SEEN)

OBJECTIVE—Hyperglycemia may increase mortality in patients who receive total parenteral nutrition (TPN). However, this has not been well studied in noncritically ill patients (i.e., patients in the nonintensive care unit setting). The aim of this study was to determine whether mean blood glucose level during TPN infusion is associated with increased mortality in noncritically ill hospitalized patients.

RESEARCH DESIGN AND METHODS—This prospective multicenter study involved 19 Spanish hospitals. Noncritically ill patients who were prescribed TPN were included prospectively, and data were collected on demographic, clinical, and laboratory variables as well as on in-hospital mortality.

RESULTS—The study included 605 patients (mean age 63.2 ± 15.7 years). The daily mean TPN values were 1.630 ± 323 kcal, 3.2 ± 0.7 g carbohydrates/kg, 1.26 ± 0.3 g amino acids/kg, and 0.9 ± 0.2 g lipids/kg. Multiple logistic regression analysis showed that the patients who had mean blood glucose levels >180 mg/dL during the TPN infusion had a risk of mortality that was 5.6 times greater than those with mean blood glucose levels <140 mg/dL (95% CI 1.47–21.4 mg/dL) after adjusting for age, sex, nutritional status, presence of diabetes or hyperglycemia before starting TPN, diagnosis, prior comorbidity, carbohydrates infused, use of steroid therapy, SD of blood glucose level, insulin units supplied, infectious complications, albumin, C-reactive protein, and HbA1c levels.

CONCLUSIONS—Hyperglycemia (mean blood glucose level >180 mg/dL) in noncritically ill patients who receive TPN is associated with a higher risk of in-hospital mortality.

Diabetes Care 36:1061–1066, 2013

Malnutrition is associated with an increased risk of hospital complications, a higher mortality rate, a longer hospital stay, and higher hospitalization costs (1). The beneficial effect of total parenteral nutrition (TPN) in improving the nutritional status of hospitalized patients who are malnourished is well established (2). However, several retrospective and prospective studies have shown that the use of TPN is an independent risk factor for the onset or aggravation of hyperglycemia independently of a history of diabetes (2,3).

Hyperglycemia in hospitalized patients is associated with a higher risk of complications and death, especially when no insulin therapy is used (3–11). So far, though, the published studies almost always involved small groups of intensive care patients (or both critically and noncritically ill patients) from just one center, and all were retrospective. In addition, these studies used classifications of previous diabetes based solely on the clinical history and failed to control the analyses for confounding variables, which may greatly influence both hyperglycemia and mortality (e.g., degree of malnourishment, severity of disease, dose of carbohydrates infused, glycemic variability). Furthermore, because the studies were retrospective, they did not ensure the homogenous collection of capillary blood glucose values, and any lack of data could have influenced results in addition to possibly affecting treatment and prevention algorithms (9).

Clinical practice guidelines and consensus statements recommend a premeal blood glucose level of <140 mg/dL for most noncritically ill patients in conjunction...
Parenteral nutrition–associated hyperglycemia

with random blood glucose values of <180 mg/dL (12,13). These cut points, however, are derived from studies undertaken in critically ill patients (who often receive TPN and enteral nutritional support), and it is not known whether the results are also applicable to noncritically ill patients receiving TPN because these patients have an increased risk of complications and mortality.

We hypothesized that hospitalized noncritically ill patients receiving TPN with appropriate blood glucose control experience less in-hospital mortality than patients with uncontrolled hyperglycemia. The aim, therefore, of this multicenter study was to determine whether blood glucose levels measured during TPN infusion in noncritically ill patients influence hospital mortality under conditions of daily clinical practice while controlling for confounding variables.

RESEARCH DESIGN AND METHODS—This multicenter study involved 19 hospitals in Spain (16 university hospitals and 3 nonuniversity hospitals). The study included all hospitalized noncritically ill patients (i.e., patients in the nonintensive care unit [ICU] setting) who started TPN as a sole source of nutrition between September and December 2010. Patients were excluded if they were in ICUs, receiving parenteral nutrition together with enteral nutrition, pregnant, or <14 years of age. The study was approved by the Research Ethics Committee of Carlos Haya Regional University Hospital, and all the participants gave written informed consent.

TPN protocol

The TPN formula at all the hospitals was provided as a total nutrient admixture (3 in 1) solution containing carbohydrates, proteins, and lipids. All patients receiving TPN were seen daily by a member of the hospital nutrition unit, who made adjustments in accordance with the relevant guidelines (14,15). Prospective measurements were made of capillary blood glucose levels every 6 h, but if the blood glucose levels were <140 mg/dL, the measurements were made every 8 h. The blood glucose monitor used was the usual model in each hospital. If a patient had hyperglycemia, insulin treatment was started, following consensus recommendations (12).

### Table 1—Patient and TPN characteristics

| Variable                              | Value     |
|---------------------------------------|-----------|
| Age (years)                           | 63.2 ± 15.7 |
| Men/women (%)                         | 56.7/43.3 |
| Days hospitalized (n)                 | 33.6 ± 26.7 |
| Days on TPN (n)                       | 13 ± 11   |
| BMI (kg/m²)                           | 25.2 ± 5.5 |
| TPN characteristics                   |           |
| Kilocalories administered             | 1.630 ± 323 |
| Kilocalories/kg body weight           | 25.3 ± 5.7 |
| Carbohydrates (g/kg)                  | 3.2 ± 0.7 |
| Amino acids (g/kg)                    | 1.26 ± 0.3 |
| Lipids (g/kg)                         | 0.9 ± 0.2 |
| Total carbohydrates (g/kg)            | 3.8 ± 0.8 |
| Type of amino acids                   |           |
| Standard formulations                 | 459 (75.9) |
| Glutamine- and branched amino acid–enriched formulations | 146 (24.1) |
| Type of lipids                        |           |
| LCT soy based                         | 90 (14.9) |
| LCT olive based                       | 124 (20.5) |
| LCT/MCT                               | 249 (41.2) |
| Omega-3 enriched                      | 139 (23.0) |
| Capillary blood glucose mean (mg/dL)  | 140 ± 36.5 |
| HbA₁c (%)                             | 5.75 ± 0.8 |
| Blood glucose SD                      | 27.2 ± 18.5 |
| Blood glucose coefficient of variation (%) | 18.4 ± 8.8 |
| CRP level (mg/L)                      | 94.3 ± 96.3 |
| Albumin level (g/dL)                  | 2.65 ± 0.62 |
| Malnutrition according to SGA         |           |
| Normally nourished                    | 214 (35.4) |
| Moderate malnutrition                 | 245 (40.5) |
| Severe malnutrition                   | 146 (24.1) |
| Diagnosis                             |           |
| Surgery                               | 360 (59.5) |
| Oncology (solid and hematologic)      | 114 (18.8) |
| Digestive                             | 89 (14.7) |
| Infectious disorders                  | 42 (6.9)  |
| Diabetes status before TPN infusion   |           |
| Normal                                | 308 (50.9) |
| Known and unknown diabetes            | 166 (27.4) |
| Hyperglycemia without diabetes        | 131 (21.7) |

Data are means ± SD or n (%) unless otherwise indicated. LCT, long-chain triglycerides; MCT, medium-chain triglycerides.

© 2013 by the American Diabetes Association. DOI: 10.2337/dc12-1379
Data were recorded on demographic variables; diagnosis on admission; prior comorbidity (history of kidney or liver failure, respiratory or cardiac disease, transplantation); anthropometric data (weight, height, BMI); type of TPN; concomitant prescription of steroids, somatostatin, tacrolimus, or cyclosporin; and nutritional assessment by subjective global assessment (SGA) before starting TPN (16). The mean daily insulin dose was also recorded.

Before starting the TPN infusion, a blood sample was drawn to measure the glycated hemoglobin, following the international recommendations for standardization of the HbA1c measurement (17). Measurements were also made of fasting plasma blood glucose, albumin, and C-reactive protein (CRP) levels (with an autoanalyzer) at the laboratories of each hospital.

Patients were considered to have known diabetes if they had a documented history of diabetes. Patients were considered to have unknown diabetes if there was no record of having had diabetes but the HbA1c was \( \geq 6.5\% \) (18). Any other patient with fasting plasma glucose levels \( \geq 126 \text{ mg/dL} \) was considered to have hyperglycemia without diabetes. Hypoglycemia was considered to be a capillary blood glucose level \(<70 \text{ mg/dL}\). The blood glucose variance was estimated from the SD of the mean blood glucose levels and their coefficient of variation.

The primary end point was all-cause in-hospital death. Other clinical outcome parameters were the number of days in the hospital and infectious complications, as recorded on the patient charts.

### Statistical study

The comparisons between the qualitative variables were done with the \( \chi^2 \) test, with Fisher correction when necessary. The distribution of the quantitative variables was examined with the Kolmogorov-Smirnov test. The differences between the quantitative variables were analyzed with the Student \( t \) test or ANOVA for two or more samples, respectively. Non-parametric tests (Mann-Whitney or Kruskal-Wallis) were used when the study variables did not follow a normal distribution. The significant associations were later included in multivariate logistic regression models, controlling also for other variables such as age, sex, the presence of diabetes or hyperglycemia before the administration of TPN, insulin dose per kilogram body weight, and glycated hemoglobin level. For all the calculations, significance was set at \( P < 0.05 \) for two tails.

#### RESULTS

The study included 605 patients, with a mean of 32 patients per hospital (range 19–55). The characteristics of the patients and the TPN infused are shown in Table 1. The mean HbA1c according to diabetes status was 5.3 \( \pm 0.5\% \) normal (\( n = 308 \)); 5.7 \( \pm 0.4\% \) hyperglycemia without diabetes (\( n = 166 \)); 7.2 \( \pm 1.0\% \) unknown diabetes (\( n = 23 \)); and 6.6 \( \pm 1.1\% \) known diabetes (\( n = 108 \)). TPN was started 10 \( \pm 14 \) days after admission; 433 (71\%) patients received insulin at some time during the TPN infusion (55% subcutaneously, 36% in the bag and subcutaneously, and 9\% with insulin perfusion independently of TPN).

There were 58 in-hospital deaths (9.6\%). Table 2 shows the characteristics of the patients who died and of those who survived. Significant differences were found in age, length of stay, BMI, total

| Table 2—Characteristics of the patients according to the presence of hospital mortality |
|-----------------|-------|-------|---|
| Variable                        | No    | Yes   | \( P \) value |
| Patients (n)                   | 547 (90.4) | 58 (9.6) |   |
| Age (years)                    | 62.7 \( \pm 15.9 \) | 67.9 \( \pm 12.0 \) | 0.003 |
| Days hospitalized (n)          | 32.7 \( \pm 26.1 \) | 42.0 \( \pm 31.1 \) | 0.03 |
| Days on TPN (n)                | 12.9 \( \pm 11.1 \) | 15.1 \( \pm 11.2 \) | NS |
| BMI (kg/m\(^2\))               | 25.4 \( \pm 5.6 \) | 23.6 \( \pm 4.7 \) | 0.023 |
| Total kilocalories administered through TPN | 1,637.5 \( \pm 327.2 \) | 1,567.5 \( \pm 278 \) | NS |
| Kilocalories/kg body weight    | 24.9 \( \pm 5.1 \) | 26.3 \( \pm 5.4 \) | NS |
| Total carbohydrates (TPN + dextrose-containing solutions) (g/kg) | 3.7 \( \pm 0.8 \) | 4.4 \( \pm 0.9 \) | 0.004 |
| Amino acids (g/kg)             | 1.26 \( \pm 0.3 \) | 1.30 \( \pm 0.3 \) | NS |
| Lipids (g/kg)                  | 0.94 \( \pm 0.2 \) | 0.98 \( \pm 0.3 \) | NS |
| Capillary blood glucose mean (mg/dL) | 138.5 \( \pm 34.8 \) | 154.2 \( \pm 48.2 \) | 0.02 |
| HbA1c (%)                      | 5.7 \( \pm 0.8 \) | 6.1 \( \pm 1.3 \) | NS |
| Blood glucose SD               | 26.6 \( \pm 18.2 \) | 33.2 \( \pm 21.2 \) | 0.01 |
| Blood glucose coefficient of variation (%) | 18.2 \( \pm 8.6 \) | 20.5 \( \pm 10.0 \) | NS |
| CRP level (mg/L)               | 91.3 \( \pm 95 \) | 122.5 \( \pm 104.5 \) | 0.026 |
| Albumin level (g/dL)           | 2.7 \( \pm 0.6 \) | 2.4 \( \pm 0.6 \) | 0.003 |
| Insulin units/kg body weight   | 0.17 \( \pm 0.4 \) | 0.29 \( \pm 0.4 \) | 0.013 |
| SGA                            |        |       |  |
| Normally nourished             | 205 (95.8) | 9 (4.2) |  |
| Moderate malnutrition          | 221 (90.2) | 24 (9.8) |  |
| Severe malnutrition            | 121 (82.9) | 25 (17.1) | <0.001 |
| Use of corticosteroids          |        |       |  |
| No                             | 459 (92) | 40 (8) |  |
| Yes                            | 88 (83) | 18 (17) | 0.01 |
| Diagnosis                      |        |       |  |
| Surgery                        | 336 (93.3) | 24 (6.7) |  |
| Oncology (solid and hematologic) | 92 (80.7) | 22 (19.3) |  |
| Digestive                      | 84 (94.4) | 5 (5.6) |  |
| Infectious disorders           | 35 (83.3) | 7 (16.7) | 0.001 |
| Diabetes status before TPN infusion | 282 (91.6) | 26 (8.4) |  |
| Normal                         | 151 (91) | 15 (9) |  |
| K n o w n a n d u n k n o w n d i a b e t e s   | 114 (87) | 17 (13) | NS |
| Previous comorbidity           |        |       |  |
| No                             | 421 (92.3) | 35 (7.7) |  |
| Yes                            | 126 (84.6) | 23 (15.4) | 0.01 |
| Infectious complications       | 456 (92.9) | 35 (7.1) |  |
| Yes                            | 91 (79.8) | 23 (20.2) | <0.001 |

Data are mean \( \pm \) SD or n (%).
Parenteral nutrition–associated hyperglycemia

grams of carbohydrates infused, mean capillary blood glucose level, SD of the blood glucose levels, CRP and albumin levels, degree of malnutrition, steroid therapy, admission diagnosis, prior complications, and the development of infectious complications during admission. However, the presence of diabetes or hyperglycemia before starting TPN was not associated with a greater mortality (Table 2) or a longer hospital stay. Furthermore, no differences were found for death or mean hospital stay between the patients with diabetes and those with hyperglycemia without diabetes. Of the 605 patients, 41 (6.9%) had blood glucose levels <70 mg/dL at some time; 57 (9.4%) received octreotide or somatostatin, and 13 (2.1%) received tacrolimus or cyclosporin. However, no association was found between the presence of hypoglycemia or treatment with octreotide, somatostatin, or immunosuppressive drugs and a greater risk of mortality. Furthermore, no significant differences were found in mortality according to the type of amino acids or lipids infused.

Table 3 summarizes the characteristics of the patients according to their mean capillary blood glucose levels (<140 mg/dL, 140–180 mg/dL, and >180 mg/dL) on all the days TPN was infused. Significant differences were found in age, BMI, total kilocalories given in the TPN, mean capillary blood glucose levels, HbA1c, SD of the capillary blood glucose levels, coefficient of variation of the blood glucose levels, CRP, units of insulin given per kilogram body weight, and type of insulin treatment used.

**Table 3—Differences between subjects depending on mean capillary blood glucose level**

| Variable                        | <140 mg/dL | 140–180 mg/dL | >180 mg/dL | P value |
|---------------------------------|------------|---------------|------------|---------|
| Patients                        | 370 (61.2) | 175 (28.9)    | 60 (9.9)   |         |
| Age (years)                     | 61.1 ± 16.6| 67.2 ± 13.4   | 65.1 ± 13.7| <0.001  |
| Days hospitalized (n)           | 33.3 ± 27.7| 33.5 ± 23.4   | 37.9 ± 30.6| NS      |
| Days on TPN (n)                 | 13.9 ± 11.6| 12.1 ± 11.1   | 11.2 ± 7.1 | 0.08    |
| BMI (kg/m²)                     | 24.6 ± 5.6 | 25.8 ± 5.2    | 27.3 ± 5.6 | 0.001   |
| Total kilocalories administered | 1,597 ± 324| 1,655 ± 296   | 1,758 ± 354| 0.001   |
| Through TPN                     |            |               |            |         |
| Kilocalories/kg body weight     | 25.1 ± 5.3 | 25.0 ± 5.1    | 24.7 ± 4.0 | NS      |
| Total carbohydrates (g/kg)      | 3.7 ± 0.8  | 4.0 ± 0.9     | 3.5 ± 0.6  | NS      |
| Amino acids (g/kg)              | 1.27 ± 0.3 | 1.25 ± 0.2    | 1.26 ± 0.2 | NS      |
| Lipids (g/kg)                   | 0.94 ± 0.2 | 0.96 ± 0.2    | 0.90 ± 0.2 | NS      |
| Capillary glucose mean (mg/dL)  | 119.0 ± 13.1| 156.9 ± 11.6  | 224.6 ± 39.9| <0.001  |
| HbA1c (%)                       | 5.5 ± 0.6  | 6.0 ± 0.8     | 6.9 ± 1.2  | <0.001  |
| Blood glucose SD                | 18.8 ± 8.1 | 33.8 ± 15.4   | 60.3 ± 27.5| <0.001  |
| Coefficient of variation (%)    | 15.7 ± 6.3 | 21.4 ± 9.3    | 27.2 ± 11.8| <0.001  |
| CRP level (mg/L)                | 84.6 ± 91.1| 107.9 ± 104.1| 124.5 ± 99.4| 0.004   |
| Albumin level (g/dL)            | 2.7 ± 0.6  | 2.7 ± 0.6     | 2.5 ± 0.6  | 0.07    |
| Insulin units/kg body weight    | 0.07 ± 0.2 | 0.29 ± 0.5    | 0.60 ± 0.9 | <0.001  |
| Death                           | 25 (6.8)   | 19 (10.9)     | 14 (23.3)  | <0.001  |
| Infectious complications        | 57 (15.4)  | 44 (25.1)     | 13 (21.7)  | 0.026   |
| Type of insulin treatment used  |            |               |            |         |
| None                            | 161 (43.5) | 11 (6.3)      | 0 (0)      |         |
| Subcutaneous route (without intravenous insulin) | 134 (36.2) | 86 (49.1) | 20 (33.3) |
| Intravenous insulin (added to the TPN bag) | 55 (14.9) | 61 (34.9) | 39 (65) |
| Intravenous insulin infusion therapy | 20 (5.4) | 17 (9.7) | 1 (1.7) | <0.001 |

Data are mean ± SD or n (%).
some studies (5,6,8) but not all (3,9–11). Moreover, the use of intensive insulin therapy in noncritically ill patients seems to reduce the risk of infections (23). In the present study, the incidence of infectious complications was greater in patients with higher mean blood glucose values and in those who died, strengthening the idea of the role of these complications in outcome and mortality.

In humans, van Der Voort et al. (4) found that even low amounts of infused glucose were associated with increased mortality when glucose levels were not controlled. Part of the disparity between the results in the different papers on intensive treatment in ICU patients (19,24,25) could be the result of the nutritional therapy used in the different studies.

Hypoglycemia is the most common complication associated with inpatient insulin therapy, and it could increase mortality (26). In the present study, the prevalence of hypoglycemia was very low, and in fact, it was not associated with worse outcomes. The fact that the patients were not critically ill (less severe), that the patients started from a low baseline HbA1c (even the diabetic patients), and the mode of delivery of the insulin (mostly in the bag or subcutaneously) may have influenced the results.

Glycemic variability has been suggested to be a significant independent predictor of ICU and hospital mortality (27,28). The SD in the present study was higher in patients who died, although the association lost significance after correcting for the other variables in the multivariate model. Although the variability is a factor that can contribute to the prognosis of these patients, hyperglycemia per se would appear to be the most contributing factor in noncritically ill patients receiving TPN.

Because the present sample comprised a heterogeneous population of noncritically ill patients from different centers, we used as markers of severity the measurement of CRP and albumin levels, which are also associated with worse outcomes and mortality in inpatients receiving artificial nutrition (29). As expected, the albumin levels were lower and the CRP levels higher in the patients who died, and CRP levels were higher in relation to blood glucose control. After adjusting for other variables, CRP level still contributed significantly in the multivariate model, strengthening the possible role of inflammation and the severity of the underlying disorder on complications and mortality in noncritically ill patients receiving TPN.

Malnutrition is associated with worse outcomes in hospitalized patients (1,30) and, therefore, could be an important confounding factor when interpreting the results of other studies that either failed to evaluate it or just included the BMI (4–6,8–11). The SGA is a simple method, and it has been used in many studies to predict adequately morbidity and mortality in hospitalized patients (16,31). In the present study, the risk of dying was three times greater in the severely malnourished patients compared with the normally nourished patients. Malnutrition together with hyperglycemia could be one of the most conditioning factors related to poor prognosis.

The use of special amino acid (e.g., enriched with glutamine) or lipid (based on olive oil or supplemented with omega-3 fatty acids) formulas may be beneficial to prevent or treat hyperglycemia (32,33), and the use of steroids could increase it (34), possibly increasing morbidity and mortality. We found no differences that depended on the type of macronutrient used, although the patients in the present series who received corticosteroids experienced greater mortality; nevertheless, this association was not significant in the multivariate analysis. The presence of accompanying diseases before hospital admission was a condition of in-hospital mortality, as in other studies (11).

The present study is not exempt from limitations. First, the blood samples were not centralized or the same blood glucose monitor was not used, which could contribute to small under- or overestimates of the real blood glucose values. Second, apart from infections, no other complications were recorded during the admission. Third, we did not establish a causal relation between capillary blood glucose levels on admission and mortality.

In conclusion, the results show that hyperglycemia in noncritically ill patients receiving TPN is associated with increased in-hospital mortality. The data suggest that the goal of metabolic control in noncritically ill patients (with or without diabetes) receiving TPN should be to reach a mean blood glucose level of <180 mg/dL. This study opens the door to further prospective studies in noncritically ill patients to determine whether stricter blood glucose control during TPN infusion improves the outcome for the patients and reduces mortality.

Acknowledgments—The Spanish Society of Endocrinology and Nutrition provided help with the publication expenses of the manuscript.

Table 4—Logistic regression analysis: adjusted risk of death during hospitalization

|                      | B     | Odds ratio | Lower | Upper | P value |
|----------------------|-------|------------|-------|-------|---------|
| Age                  | 0.040 | 1.041      | 1.013 | 1.070 | 0.004   |
| CRP level            | 0.004 | 1.004      | 1.001 | 1.007 | 0.05    |
| Previous malnutrition (SGA) |       | | | | |
| Normally nourished   |       | | | | |
| Moderate malnutrition| 0.55  | 1.73       | 0.62  | 4.86  | 0.29    |
| Severe malnutrition  | 1.12  | 3.05       | 1.01  | 9.23  | 0.048   |
| Mean blood glucose level during TPN | | | | | |
| <140 mg/dL           |       | | | | |
| 140–180 mg/dL        | 0.62  | 1.86       | 0.78  | 4.43  | 0.159   |
| >180 mg/dL           | 1.72  | 5.60       | 1.47  | 21.39 | 0.01    |
| Carbohydrates g/kg body weight | 0.59  | 1.80       | 1.18  | 2.76  | 0.007   |
| Diagnosis on admission |       | | | | |
| Digestive            |       | | | | |
| Oncology             | 1.89  | 6.63       | 1.64  | 26.83 | 0.008   |
| Infectious disorders | 0.51  | 1.67       | 0.31  | 9.07  | 0.551   |
| Infectious complications during hospitalization | 1.38  | 3.98       | 1.87  | 8.45  | 0.000   |

Also included in the model but without statistical significance were sex, diabetes status before TPN, use of corticosteroids, blood glucose variability (SD), glycated hemoglobin, insulin units/kg body weight, presence of comorbidity before TPN, and albuminemia.
Parenteral nutrition—associated hyperglycemia

The funder played no role in the conduct of the study, collection of data, management of the study, analysis of data, interpretation of data, or preparation of the manuscript.

No potential conflicts of interest relevant to this article were reported.

G.O. and M.J.T. contributed to the conception and design of the study; acquisition, analysis, and interpretation of the data; statistical analysis; and drafting of the manuscript. J.Oc., C.C.-G., M.D.B.-P., A.V.-C., C.A.-I., J.OI., M.C.C.-G., A.G.-M., F.B.-R., R.P.Q.-T., L.Ga., P.M., L.Ch., R.B., P.P., M.F., A.Z.-J., P.M., M.D., M.J.C., A.V.-B., J.R.U., C.A.-V., A.R., L.B., P.G.-P., A.M.-G., E.M., D.O., J.L.P., and M.C.T. contributed to the data acquisition and critical review of the manuscript. G.O. and M.J.T. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Parts of this study were presented in abstract form at the 27th Congress of the Spanish Society of Parenteral and Enteral Nutrition, Madrid, Spain, 8–11 May 2012.

The authors thank the patients for their participation in the study.

References
1. Correia MI, Waitzberg DL. The impact of malnutrition on morbidity, mortality, length of hospital stay and costs evaluated through a multivariate model analysis. Clin Nutr 2003;22:235–239
2. Ziegler TR. Parenteral nutrition in the critically ill patient. N Engl J Med 2009;361:1088–1097
3. Lee H, Koh SO, Park MS. Higher dextrose delivery via TPN related to the development of hyperglycemia in non-diabetic critically ill patients. Nutr Res Pract 2011;5:450–454
4. vanDer Voort PH, Feenstra RA, Bakker AJ, Heide L, Boerma EC, van der Horst IC. Intra-venous glucose intake independently related to intensive care unit and hospital mortality: an argument for glucose toxicity in critically ill patients. Clin Endocrinol (Oxf) 2006;64:141–145
5. Lin LY, Lin HC, Lee PC, Ma WY, Lin HD. Hyperglycemia correlates with outcomes in patients receiving total parenteral nutrition. Am J Med Sci 2007;333:261–265
6. Cheung NW, Napier B, Zaccaria C, Fletcher JP. Hyperglycemia is associated with adverse outcomes in patients receiving total parenteral nutrition. Diabetes Care 2005;28:2367–2371
7. Sheean PM, Freels SA, Helton WS, Braunischweig CA. Adverse clinical consequences of hyperglycemia from total parenteral nutrition exposure during hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12:656–664
8. Pasquel FJ, Spiegelman R, McCauley M, et al. Hyperglycemia during total parenteral nutrition: an important marker of poor outcome and mortality in hospitalized patients. Diabetes Care 2010;33:739–741
9. Sarkisian S, Fenton TR, Shaheen AA, Raman M. Parenteral nutrition–associated hyperglycemia in noncritically ill inpatients is associated with higher mortality. Can J Gastroenterol 2010;24:453–457
10. Fuji S, Kim SW, Mori S, et al. Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation. Transplantation 2007;84:814–820
11. Faligcia M, Freyberg RW, Almenoff PL, D’Alessio DA, Render ML. Hyperglycemia–related mortality in critically ill patients varies with admission diagnosis. Crit Care Med 2009;37:3001–3009
12. Moghissi ES, Korytkowski MT, DiNardo M, et al; American Association of Clinical Endocrinologists, American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009;32:1119–1131
13. Umpierrez GE, Hellman R, Korytkowski MT, et al; Endocrine Society. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012;97:16–38
14. Bozzetti F, Forbes A. The ESPEN clinical practice guidelines on parenteral nutrition: present status and perspectives for future research. Clin Nutr 2009;28:359–364
15. McClave SA, Martindale RG, Vanek VW, et al; A.S.P.E.N. Board of Directors; American College of Critical Care Medicine; Society of Critical Care Medicine. Guidelines for the provision and assessment of nutrition support therapy in the critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). J Parenter Enteral Nutr 2009;33:277–316
16. Detsky AS, McLaughlin JR, Baker JP, et al. What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr 1987;11:8–13
17. Hanas R, John G; International HBA 1c Consensus Committee. 2010 consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Diabetes Care 2010;33:1903–1904
18. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl 1):S62–S69
19. Corathers SD, Faligcia M. The role of hyperglycemia in acute illness: supporting evidence and its limitations. Nutrition 2011;27:276–281
20. Lepper PM, Ott S, Niësches E, et al; German Community Acquired Pneumonia Competence Network. Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. BMJ 2012;344:e3397
21. Carral F, Olveira G, Aguilar M, et al. Hospital discharge records under-report the prevalence of diabetes in inpatients. Diabetes Res Clin Pract 2003;59:145–151
22. Miller KR, Lawson CM, Smith VL, Harbrecht BG. Carbohydrate provision in the era of tight glucose control. Curr Gastroenterol Rep 2011;13:388–394
23. Murad MH, Coburn JA, Coto-Vglasies F, et al. Glycemic control in non-critically ill hospitalized patients: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012;97:49–58
24. Van den Bergh G, Schetz M, Vlasselaers D, et al. Clinical review: intensive insulin therapy in critically ill patients: NICE-SUGAR or Leuven blood glucose target? J Clin Endocrinol Metab 2009;94:3163–3170
25. Marik PE, Preiser JC. Toward understanding tight glycemic control in the ICU: a systematic review and meta-analysis. Chest 2010;137:544–551
26. Finnie S, Chittock DR, Su SY, et al; NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283–1297
27. Kinsley JS. Glycemic variability and mortality in critically ill patients: the impact of diabetes. J Diabetes Sci Tech 2009;3:1292–1301
28. Hermanides J, Vriesendorp TM, Bosman RJ, Zandstra DF, Hoekstra JB, Devries JH. Glucose variability is associated with intensive care unit mortality. Crit Care Med 2010;38:838–842
29. Donini LM, Savina C, Ricciardi LM, et al. Predicting the outcome of artificial nutrition by clinical and functional indices. Nutrition 2009;25:11–19
30. Lobo Tâmer G, Ruiz López MD, Pérez de la Cruz AJ. Hospital malnutrition: relation between the hospital length of stay and the rate of early readmissions. Med Clin (Barc) 2009;132:377–384 [in Spanish]
31. Keith JN. Bedside nutrition assessment, past, present, and future: a review of the Subjective Global Assessment. Nutr Clin Pract 2008;23:410–416
32. Gosmanov AR, Umpierrez GE. Medical nutrition therapy in hospitalized patients with diabetes. Curr Diab Rep 2012;12:93–100
33. Grau T, Bonet A, Miambres E, et al; Metabolism, Nutrition Working Group, SEMICYUC, Spain. The effect of L-alanyl-L-glutamine dipeptide supplemented total parenteral nutrition on infectious morbidity and insulin sensitivity in critically ill patients. Crit Care Med 2011;39:1263–1268
34. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009;15:469–474